眼内薬物投与による網脈絡膜疾患に対する治療の研究

• Material Type: 文書・図像類
• Title: 眼内薬物投与による網脈絡膜疾患に対する治療の研究
• Author/Editor: 輪島, 良平; Wajima, Ryohei
• Author Heading: 輪島, 良平; Wajima, Ryohei
• Publication Date: 1999-03-08
• Publication Date (W3CDTF): 1999-03-08
• Alternative Title: The Toxicity and Pharmacokinetics of Fluoroquinolones
• Periodical title: 平成7(1995)年度 科学研究費補助金 一般研究(C) 研究成果報告書概要 = 1995 Fiscal Year Final Research Report Summary
• No. or year of volume/issue: 1994 – 1995
• Volume: 1994 – 1995
• Pages: 2p.-
• Text Language Code: jpn
• Subject Heading: レボフロキサシン; 網膜毒性; 網膜電図; 視覚誘発電位; 組織学的検討; 眼内動態; メラニン; levofloxacin; ocular toxicity; melanin; electroretinogram; intraocular penetration; pharmacokinetics
• Target Audience: 一般
• Note (General): 前年度の研究では、レボフロキサシンの経口投与後の眼内動態および摘出眼杯網膜電図(ERG)を用いたレボフロキサシンの眼毒性について検討した。今年度はレボフロキサシン硝子体内注入のウサギ網膜に及ぼす影響を電気生理学的および組織学的に検討した。レボフロキサシン200または500μgの硝子体内注入では白色、有色ウサギともにERG各波に変化はみられなかったが、1000または2000μgの硝子体内注入では一過性に律動様小波振幅の低下がみられた。視覚誘発電位および組織学的検討ではいずれの注入量においても変化はみられなかった。.レボフロキサシン200または500μgの硝子体内注入はウサギ網膜に明らかな影響を与えないことが示された。そこでレボフロキサシン500μg硝子体内注入後の眼内動態について検討した。注入後のレボフロキサシンの硝子体内濃度は有色および白色ウサギともに同様な動態を示し、主要な細菌性眼内炎の起因菌のMIC_<90>を少なくとも24時間は凌駕する。その他のメラニン非含有組織内のレボフロキサシン濃度は、白色ウサギと有色ウサギとの間に有意な差はみられなかった。虹彩毛様体および網膜色素上皮・脈絡膜のメラニン含有眼組織内では、レボフロキサシン濃度は有色ウサギでは白色ウサギに比し測定したいずれの時点でも有意に高く、1週間後における有色ウサギの網膜色素上皮・脈絡膜には10μg/g以上のレボフロキサシンが検出された。レボフロキサシンがメラニン含有眼組織内に高濃度に移行し蓄積することが明らかになった。; Fluoroquinolones have recently playd an important role in treatment of infectious endophthalmitis because of an increase of delayd-onset endophthalmitis after cataract surgery and methicillin-resistant Staphylococcus aureus infection. Ocular toxicity of fluoroquinolones, however, is concerned from the viewpoint of its melanin-affinity. The ocular tolerance and dynamics of levofloxacin (LVFX), a new fluoroquinolone agent, were studied in the present research.The effects of LVFX and its isomer (DR-3354) on the retina were evaluated by in-vitro electroretinogram (ERG) in albino rabbits. The ERG was unchanged during perfusion with 100 and 300muM of levofloxacin, and 100muM of DR-3354. The amplitude of the oscillatory potential was diminished with 300muM of DR-3354 and 500muM of LVFX.The intraocular penetration of LVFX was studied in albino and pigmented rabbits after oral administration of ^<14>C-LVFX.The radioactivity of the eyeball of albino rabbits in the autoradiogram was much higher at 1hr than 2 or 6hr after administration. On the other hand, the distribution of radioactivity in pigmented rabbits was similar at 1,2, and 6hr after administration. The LVFX concentration in the melanin-containing tissues such as the iris-ciliary body and the choroid-retina was significantly higher in pigmented rabbits than in albino rabbits after oral administraion. These results indicate that the intraocular pharmacokinetics of LVFX are markedly affected by its affinity for melanin.The effects of intravitreal injection of LVFX on the ERG were studied to establish the non-toxic intravitreal dosage of LVFX.The oscillatory potential transiently deteriorated with 1000 and 2000 mug doses of LVFX in albino and pigmented rabbits. No ERG changes were observed with 200 and 500 mug of LVFX.These results indicate that intravitreal injections of 200 and 500 mug of LVFX are nontoxic to the rabbit retina.The pharmacokinetics after an intravitreal injection of 500 mug of LVFX were studied in albino and pigmented rabbits. The intravitreal concentration of LVFX was similar in both albino and pigmented rabbits at each measuring point. The LVFX concentration in the melanin-containing tissues such as the iris-ciliary body and the choroid-retina was significantly higher in pigmented rabbits than in albino rabbits after intravitreal injection.The effects of low-molecular-weight heparin, colchicine and interferon beta on in-vitro ERG were studied in albino rabbits. The ERG were unchanged during perfusion with 5 and 20 IU/ml low-molecular-weight heparin, 25 and 50 mu g/ml colchicine or 5000 and 10000 IU/ml interferon beta.These results indicate that LVFX may be clinically applicable for the treatment of infectious eye disease.; 研究課題/領域番号:06671755, 研究期間(年度):1994 – 1995; 出典：研究課題「眼内薬物投与による網脈絡膜疾患に対する治療の研究」課題番号06671755（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） （https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-06671755/066717551995kenkyu_seika_hokoku_gaiyo/）を加工して作成
• DOI: 10.24517/00066427
• Source: https://kanazawa-u.repo.nii.ac.jp/?action=repository_action_common_download&item_id=60176&item_no=1&attribute_id=26&file_no=1
• Access Restrictions: 限定公開
• Rights (production): CC BY-NC-ND
• Related Material: https://kaken.nii.ac.jp/search/?qm=30201164; https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-06671755/; https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-06671755/066717551995kenkyu_seika_hokoku_gaiyo/
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 金沢大学 : 金沢大学学術情報リポジトリKURA